Alterity Therapeutics (ATHE) Receivables (2009 - 2026)

Alterity Therapeutics has reported Receivables for 18 years, with the latest figure at $5.5 million in Q2 2026.

• On a quarterly basis, Receivables rose 116.57% year-over-year to $5.5 million in Q2 2026; TTM through Jun 2026 was $5.5 million, a 116.57% increase from a year earlier, with the FY2026 full-year figure at $5.5 million, up 116.57% from the prior year.
• Receivables was $5.5 million for Q2 2026 at Alterity Therapeutics, up from $4.5 million in the prior quarter.
• The five-year high for Receivables was $5.5 million in Q2 2026, with the low at $40416.8 in Q2 2024.
• Average Receivables over 5 years is $3.1 million, with a median of $3.7 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Receivables sank 97.44% in 2023, then jumped 6139.43% in 2025.
• Over 5 years, Receivables stood at $4.6 million in 2022, then fell by 16.22% to $3.9 million in 2023, then decreased by 4.58% to $3.7 million in 2024, then advanced by 20.86% to $4.5 million in 2025, then rose by 21.56% to $5.5 million in 2026.
• The last three Receivables figures came in at $5.5 million (Q2 2026), $4.5 million (Q4 2025), and $2.5 million (Q2 2025), per Business Quant data.